Transaction · 0001193125-26-377309

KENNEY CHRISTOPHER JOHN

KENNEY CHRISTOPHER JOHN, CMO, reported an open-market or private sale at Xenon Pharmaceuticals Inc. involving 700.000000 shares for an estimated $42683.62. Reported holdings after the transaction were 2.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCMO
XENEXenon Pharmaceuticals Inc.
Filing timeSep 01
Trade dateAug 28, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$60.72
Pre-filing
1mo ago +3.9%1w ago +0.1%1d ago +0.0%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

XENE price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
XENE since 2026-09-01Filed 2 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-377309
Common Shares
Transaction date
Aug 28, 2026
Filed Sep 01, 2026, 01:59 AM · 4d delay
Shares
700 sh
$6.09k per share
Estimated value
-$4.26M
Computed from shares × price
Holdings after
2 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Holdings Reduction Repeat Seller 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026.

  2. F2

    The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multi…

  3. F3

    The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multi…

  4. F4

    The number of shares beneficially owned following the reported transactions reflects an upward adjustment of one share from the reporting person's previous Form 4 filed on March 13, 2026, based on upd…

Original filing · 0001193125-26-377309
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

XENE